

David T Yeung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9575174/publications.pdf>

Version: 2024-02-01

29
papers

525
citations

759233

12
h-index

677142

22
g-index

31
all docs

31
docs citations

31
times ranked

523
citing authors

#	ARTICLE	IF	CITATIONS
1	A Rodent Model of Sulfur Mustard Hematologic Toxicity for the Efficacy Evaluation of Candidate Medical Countermeasures. <i>Military Medicine</i> , 2022, 187, e106-e115.	0.8	5
2	Supporting discovery and development of medical countermeasures for chemical injury to eye and skin. <i>Experimental Eye Research</i> , 2022, 221, 109156.	2.6	6
3	The Kv7 Modulator, Retigabine, is an Efficacious Antiseizure Drug for Delayed Treatment of Organophosphate-induced Status Epilepticus. <i>Neuroscience</i> , 2021, 463, 143-158.	2.3	2
4	Screening for Efficacious Anticonvulsants and Neuroprotectants in Delayed Treatment Models of Organophosphate-induced Status Epilepticus. <i>Neuroscience</i> , 2020, 425, 280-300.	2.3	17
5	Ocular Surface “ Merging Challenges and Opportunities. <i>Translational Vision Science and Technology</i> , 2020, 9, 3.	2.2	10
6	The National Institutes of Health Chemical Countermeasures Research Program (NIH CCRP): A collaborative opportunity to develop effective and accessible chemical medical countermeasures for the American people. <i>Drug Development Research</i> , 2020, 81, 907-910.	2.9	7
7	Considerations in developing medical countermeasures against chemical ocular toxicity. <i>Toxicology Letters</i> , 2020, 334, 1-3.	0.8	3
8	Supporting Fundamental Chemical Toxicology Research To Inform Medical Countermeasure Developments: The National Institutes of Health Chemical Countermeasures Research Program. <i>Chemical Research in Toxicology</i> , 2020, 33, 855-859.	3.3	8
9	An Overview of the NIAID/NIH Chemical Medical Countermeasures Product Research and Development Program *. , 2019, , 615-626.		1
10	Kinetic analysis of oxime-assisted reactivation of human, Guinea pig, and rat acetylcholinesterase inhibited by the organophosphorus pesticide metabolite phorate oxon (PHO). <i>Pesticide Biochemistry and Physiology</i> , 2018, 145, 93-99.	3.6	8
11	Evaluating the broad-spectrum efficacy of the acetylcholinesterase oximes reactivators MMB4 DMS, HLÅ†-7 DMS, and 2-PAM Cl against phorate oxon, sarin, and VX in the Hartley guinea pig. <i>NeuroToxicology</i> , 2018, 68, 142-148.	3.0	10
12	Synthesis and Storage Stability of Diisopropylfluorophosphate. <i>Journal of Chemistry</i> , 2016, 2016, 1-5.	1.9	23
13	Efficacy of Recommended Prehospital Human Equivalent Doses of Atropine and Pralidoxime Against the Toxic Effects of Carbamate Poisoning in the Hartley Guinea Pig. <i>International Journal of Toxicology</i> , 2016, 35, 344-357.	1.2	7
14	Acute toxicity of phorate oxon by oral gavage in the Sprague-Dawley rat. <i>Fundamental Toxicological Sciences</i> , 2016, 3, 195-204.	0.6	5
15	Toxicity and median effective doses of oxime therapies against percutaneous organophosphorus pesticide and nerve agent challenges in the Hartley guinea pig. <i>Journal of Toxicological Sciences</i> , 2016, 41, 511-521.	1.5	13
16	Assessing the therapeutic efficacy of oxime therapies against percutaneous organophosphorus pesticide and nerve agent challenges in the Hartley guinea pig. <i>Journal of Toxicological Sciences</i> , 2015, 40, 759-775.	1.5	7
17	QuEChERS-based approach toward the analysis of two insecticides, methomyl and aldicarb, in blood and brain tissue. <i>Analytical Methods</i> , 2015, 7, 321-328.	2.7	14
18	A novel sulfur mustard (HD) vapor inhalation exposure system for accurate inhaled dose delivery. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 71, 120-128.	0.7	4

#	ARTICLE	IF	CITATIONS
19	Strategies to Enhance Medical Countermeasures After the Use of Chemical Warfare Agents on Civilians. , 2015, , 1049-1056.		2
20	A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides. Toxicology and Applied Pharmacology, 2014, 281, 254-265.	2.8	51
21	Evaluation of HemogloBindTM treatment for preparation of samples for cholinesterase analysis. Advances in Bioscience and Biotechnology (Print), 2013, 04, 1020-1023.	0.7	7
22	The CounterACT Research Network: Basic Mechanisms and Practical Applications. Proceedings of the American Thoracic Society, 2010, 7, 254-256.	3.5	42
23	Dramatic Differences in Organophosphorus Hydrolase Activity between Human and Chimeric Recombinant Mammalian Paraoxonase-1 Enzymes. Biochemistry, 2009, 48, 10416-10422.	2.5	42
24	Strategies to Enhance Medical Countermeasures After the Use of Chemical Warfare Agents on Civilians. , 2009, , 889-895.		0
25	Human Paraoxonase I: A Potential Bioscavenger of Organophosphorus Nerve Agents. , 2008, , 151-170.		13
26	A Gas Chromatographic-Mass Spectrometric Approach to Examining Stereoselective Interaction of Human Plasma Proteins with Soman*. Journal of Analytical Toxicology, 2008, 32, 86-91.	2.8	31
27	Direct detection of stereospecific soman hydrolysis by wild-type human serum paraoxonase. FEBS Journal, 2007, 274, 1183-1191.	4.7	42
28	Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates. FEBS Journal, 2005, 272, 2225-2230.	4.7	56
29	Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1702, 67-77.	2.3	71